- Home
- MRNA vs STLA Comparison
MRNA vs STLA Comparison
Compare MRNA & STLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- STLA
- Stock Information
- Founded
- MRNA 2010
- STLA 2021
- Country
- MRNA United States
- STLA Netherlands
- Employees
- MRNA N/A
- STLA N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- STLA Auto Manufacturing
- Sector
- MRNA Health Care
- STLA Consumer Discretionary
- Exchange
- MRNA Nasdaq
- STLA Nasdaq
- Market Cap
- MRNA 34.6B
- STLA 38.2B
- IPO Year
- MRNA 2018
- STLA N/A
- Fundamental
- Price
- MRNA $54.82
- STLA $13.01
- Analyst Decision
- MRNA Hold
- STLA Buy
- Analyst Count
- MRNA 16
- STLA 9
- Target Price
- MRNA $95.93
- STLA $27.34
- AVG Volume (30 Days)
- MRNA 5.0M
- STLA 10.3M
- Earning Date
- MRNA 11-07-2024
- STLA 07-25-2024
- Dividend Yield
- MRNA N/A
- STLA 12.74%
- EPS Growth
- MRNA N/A
- STLA N/A
- EPS
- MRNA N/A
- STLA 4.84
- Revenue
- MRNA $5,050,000,000.00
- STLA $188,784,956,588.00
- Revenue This Year
- MRNA N/A
- STLA N/A
- Revenue Next Year
- MRNA $5.29
- STLA $4.29
- P/E Ratio
- MRNA N/A
- STLA $2.68
- Revenue Growth
- MRNA N/A
- STLA N/A
- 52 Week Low
- MRNA $54.82
- STLA $12.74
- 52 Week High
- MRNA $170.47
- STLA $29.51
- Technical
- Relative Strength Index (RSI)
- MRNA 25.28
- STLA 33.87
- Support Level
- MRNA $55.70
- STLA $12.89
- Resistance Level
- MRNA $59.73
- STLA $13.25
- Average True Range (ATR)
- MRNA 2.17
- STLA 0.23
- MACD
- MRNA 0.29
- STLA -0.01
- Stochastic Oscillator
- MRNA 0.00
- STLA 19.34
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles, or FCA, and French-based Peugeot, or PSA, in January 2021, resulting in the fourth-largest automotive original equipment manufacturer, or OEM, by vehicle sales. In 2023 it sold 6.4 million vehicles, 44% and 30% in Europe and North America, respectively. North America is the most profitable region, contributing 53% of operating income. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroen, Opel, Alfa Romeo, and Maserati.